Lawmakers: 'Cures' bill won't sacrifice US drug safety
This article was originally published in Scrip
Executive Summary
Surrounded by patients and their advocates, a bipartisan group of leaders from the House Energy and Commerce Committee insisted during a 16 June Capitol Hill press conference a bill aimed at overhauling the US biomedical enterprise would not forgo patient safety by speeding up the drug development and approval processes.